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The metastasis-associated protein S100A4 promotes
the inflammatory response of mononuclear cells via
the TLR4 signalling pathway in rheumatoid arthritis
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Abstract
Objectives. S100A4 has been implicated in cancer and several inflammatory diseases, including RA. The
aim of the present study was to determine whether S100A4 can stimulate proinflammatory cytokine pro-
duction in mononuclear cells.
Methods. Peripheral blood mononuclear cells (PBMCs) isolated from patients with RA were stimulated
with S100A4, S100A8, S100A9 and S100A12. The production of IL-1b, IL-6 and TNF-a was measured by
ELISA. Receptor for advanced glycation end products (RAGEs) and Toll-like receptor 4 (TLR4) signalling
were examined. For signalling pathway blocking studies, inhibitors of myeloid differentiation primary re-
sponse gene 88 (MyD88), nuclear factor kappa B (NF-kB) and the mitogen activated protein (MAP) kinases
p38, extracellular signal-regulated kinase 1/2 (ERK1/2) and Jun N-terminal kinase (JNK) were used. MAP
kinase activation was evaluated by western blotting.
Results. Stimulation of PBMCs with S100A4 significantly up-regulated IL-1b, IL-6 and TNF-a production
compared with unstimulated cells (P<0.001). Importantly, the production of these cytokines was markedly
enhanced in response to S100A4 compared with S100A8 and S100A12; however, it was less pronounced
compared with S100A9. Furthermore, enhanced production of proinflammatory cytokines in S100A4-sti-
mulated PMBCs was at least partly mediated via TLR4, but not RAGEs, and by activation of the tran-
scription factor NF-kB and the MAP kinases p38 and ERK1/2.
Conclusion. This is the first study to demonstrate that S100A4 can induce an inflammatory response
mediated by TLR4 and by the activation of NF-kB and the kinases p38 and ERK1/2 in mononuclear cells
from patients with RA. Therefore S100A4 may be a potential therapeutic target for immune-mediated diseases.
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Introduction
RA is a chronic, systemic, autoimmune disease
characterized by persistent inflammation of synovial
joints, leading to progressive joint destruction. Immune
cells such as T and B cells, macrophages and dendritic
cells are recruited to affected joints where they, together
with synovial fibroblasts, produce a wide range of cyto-
kines, inflammatory mediators and matrix-degrading en-
zymes, contributing to the development of adjacent bone
erosion and cartilage destruction [1].
S100A4 protein, also referred to as mts1, FSP1, CAPL,
calvasculin, p9Ka, pEL-98, 18A2 and 42A, belongs to the
S100 family of structurally related calcium binding pro-
teins. It was originally described as a protein differentially
regulated in metastatic tumours and was established as a
metastasis-promoting factor associated with poor survival
rates in a variety of cancers [2]. However, we and others
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have recently shown enhanced S100A4 expression in sev-
eral chronic inflammatory conditions [37]. S100A4 is
increased at local sites of inflammation and in the blood
circulation of patients with RA [4]. Additionally, it correl-
ates with disease activity [5] and has both proinflamma-
tory and destructive properties [3, 5]. Moreover, S100A4
has been shown to be up-regulated and actively involved
in the pathogenesis of other immune-mediated diseases
such as inflammatory myopathies and psoriasis [6, 7].
Nevertheless, the exact mechanism leading to S100A4-
induced inflammatory reactions has not been identified.
S100A4 has been shown to bind to receptor for advanced
glycation end products (RAGEs) and to enhance MMP-13
expression via activation of nuclear factor kappa B (NF-
kB) in human chondrocytes [8]. Independent of RAGEs,
S100A4 can induce neurite outgrowth via interactions with
heparin sulphate proteoglycans at the cell surface [9],
stimulate angiogenesis through interaction with annexin
II [10] and regulate tumour progression by interacting
with the epidermal growth factor receptor [11]. Another
S100 family member, S100A12, has been reported to
bind RAGEs and thus activate proinflammatory and
tissue-destructive mediators [12]. Recent studies have
provided novel insight into the role of S100 proteins by
showing that both S100A8/9 and S100A12 exert proin-
flammatory effects via interaction with Toll-like receptor
4 (TLR4) [13, 14]. Very recently, Bjo¨rk et al. [15] revealed
that S100A4 and S100A9 proteins show an overlapping
reactivity with TLR4 and RAGEs and that these proteins
can form heterodimers with reactivity to these receptors.
Our aim was to investigate the involvement and functional
role of S100A4 in the immune response of RA mononu-
clear cells and the potential receptors and cell signalling
pathways involved in this process.
Materials and methods
Cell isolation
Peripheral blood samples were obtained from 31 patients
with RA who fulfilled the 1987 ACR criteria for the classi-
fication of RA. Detailed patient characteristics are given in
supplementary Table S1, available at Rheumatology
Online. The study was approved by the Ethical Board of
the Institute of Rheumatology and all patients provided
informed consent. Peripheral blood mononuclear cells
(PBMCs) were isolated from pooled peripheral blood sam-
ples by Ficoll-Paque density gradient centrifugation.
PBMC suspensions were adjusted at a density of
5.0105 cells per 1 ml of Advanced RPMI-1640 culture
medium (Invitrogen, Carlsbad, CA, USA) in six-well plates
and were incubated for 30 min at 37C with 5% CO2 in a
humidified atmosphere.
Cell cultures and stimulatory experiments
Cells were treated with S100A4 multimer (1 mg/ml),
S100A8 (1mg/ml), S100A9 (1 mg/ml) or S100A12 (1 mg/ml)
for 24 h. The S100 proteins were obtained from recombin-
ant His6-tagged protein by gel filtration as described pre-
viously for S100A4 [16]. The purity of the S100 proteins
was checked by adding a potent endotoxin/lipopolysac-
charide (LPS) inhibitor polymyxin B sulphate in the experi-
ments (n= 4) along with the S100 proteins (see
supplementary Fig. S1, available at Rheumatology
Online). The dose and time course were selected in ac-
cordance with our previous experiments [3, 4, 6, 16].
For inhibition studies, cells were pretreated for 30 min
with inhibitors prior to incubation with S100A4. The tested
inhibitors included the following: 10 mg/ml abRAGE (R&D
Systems, Minneapolis, MN, USA); 100mg/ml AGE-BSA
(BioVision, Mountain View, CA, USA), which is a competi-
tive RAGE ligand; 10 mg/ml abTLR-4 (BioLegend, San
Diego, CA, USA); 50mM myeloid differentiation primary
response gene 88 (MyD88) inhibitor (Imgenex, San
Diego, CA, USA); inhibitors of mitogen activated protein
(MAP) kinases, including extracellular signal-regulated
kinase (ERK) (PD98059; 2 mM), p38 (SB203580; 50 mM)
and Jun N-terminal kinase (JNK) (SP600125; 40 nM)
(Calbiochem, San Diego, CA, USA); and an inhibitor of
NF-kB, 500mM caffeic acid phenethyl ester (Tocris
Bioscience, Ellisville, MI, USA). After a 24 h incuba-
tion, conditioned medium was collected and stored
at 80C.
ELISA
The levels of TNF-a, IL-1b and IL-6 were measured in the
cell culture supernatants using ELISA kits according to the
manufacturer’s protocol (Ray Biotech, Norcross, GA,
USA). The analyses were performed using a SUNRISE
ELISA reader (Tecan, Salzburg, Austria) at 450 nm.
Protein isolation and western blotting
PBMC suspensions adjusted to a density of 20106 cells
per 4 ml of Advanced RPMI-1640 culture medium
(Invitrogen) were treated with an S100A4 multimer (1 mg/
ml) for 15, 30 and 60 min, centrifuged and washed with
PBS. For protein isolation, cell pellets were resuspended
in lysis buffer [20 mM Tris-HCl, pH 7.4, 300 mM NaCl,
0.2 mM dithiothreitol (DTT)] and lysed for 2 h at 4C.
Protein extracts (40 ml) were denatured at 70C in 2
Laemmli sample buffer at a 1:1 ratio, separated by SDS-
PAGE electrophoresis and transferred to a nitrocellulose
membrane (Bio-Rad, Hercules, CA, USA). Blots were
blocked for non-specific binding and incubated with
rabbit anti-human antibody overnight at 4C, followed by
2 h at room temperature with secondary horseradish per-
oxidase (HRP)-conjugated anti-rabbit IgG antibody.
Protein bands were visualized using the DAB Enhanced
Liquid Substrate System (Sigma, St Louis, MO, USA). The
following antibodies were used: a-tubulin, dilution 1:1000
(Cell Signaling Technology, Danvers, MA, USA; 2125);
phospho-SAPK/JNK (Thr183/Tyr185), dilution 1:1000
(Cell Signaling, 9251); phospho-p44/42 MAPK (ERK1/2)
(Thr202/Tyr204), dilution 1:1000 (Cell Signaling, 9101);
phospho-p38 MAP kinase (Thr180/Tyr182), dilution
1:1000 (Cell Signaling, 9211); anti-rabbit IgG-HRP-linked
antibody (Cell Signaling, 7074).
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Statistical analyses
S100A4 protein concentrations are expressed as the
mean (S.E.M.). The Wilcoxon test was used for compari-
sons between two variables. For all statistical evaluations,
P-values <0.05 were considered to be statistically
significant.
Results
S100A4 up-regulates proinflammatory cytokines in
PBMCs
To evaluate the proinflammatory effects of S100A4, we
stimulated PBMCs (n= 8 experiments) with the S100A4
multimer for 24 h and analysed the levels of TNF-a, IL-1b
and IL-6 in the supernatants. PBMCs treated with S100A4
significantly up-regulated the synthesis of TNF-a
[763.5 pg/ml (S.D. 80.6) vs 34.95 (8.029), P< 0.01], IL-1b
[161.4 pg/ml (S.D. 16.72) vs 3.256 (0.699), P< 0.01] and
IL-6 [845.2 pg/ml (S.D. 24.42) vs 9.957 (1.546), P< 0.01)
compared with unstimulated cells (Fig. 1A). In addition,
S100A4 exerted a significantly stronger effect on cytokine
production in contrast to S100A8 and S100A12, but a
lesser effect when compared with S100A9 (Fig. 1AC).
We also looked at the cytokine production in S100A4-
treated PBMCs from healthy individuals (n= 510). The
proinflammatory activity of S100A4 was evident, but less
pronounced, in PBMCs from healthy individuals com-
pared with those from RA patients, which could be ex-
plained by the higher responsiveness and reactivity of
PBMCs from RA patients (see supplementary Fig. S2,
available at Rheumatology Online).
S100A4 inflammatory response is mediated via TLR4
and activation of NF-kB, p38 and ERK1/2 kinases
As previously reported, the proinflammatory effects of
several members of the S100 family are mediated via
RAGEs [12] and TLR4 [13, 14]. In the present study,
PBMCs (n= 35 experiments) pretreated with the antibody
against RAGE or AGE-BSA (an alternative ligand for
RAGE) prior to S100A4 or S100A12 stimulation did not
significantly alter cytokine production compared with
PBMCs with no pretreatment (supplementary Fig. S3,
available at Rheumatology Online). We therefore
hypothesized that the RAGE receptor was not involved
in the S100A4-induced inflammatory response in
PBMCs. To address the role of TLR4, inhibitors directed
against TLR4 and MyD88 were used prior to S100A4
treatment. As shown in Fig. 1DF, incubation of PBMCs
(n= 5 experiments) with anti-TLR4 antibody before
S100A4 treatment reduced the production of IL-1b by
22.8% [from 128.1 pg/ml (S.D. 4.86) to 98.95 (7.94),
P< 0.05], IL-6 by 54.7% [from 823.3 pg/ml (S.D. 31.67) to
372.7 (79.16), P< 0.01) and TNF-a by 44.9% [from
876.0 pg/ml (S.D. 72.47) to 482.8 (68.04), P< 0.05].
Consistently the inhibition of the adaptor protein MyD88
in S100A4-stimulated PBMCs (n= 45) significantly
reduced IL-1b production by 90.1% [from 128.1 pg/ml
(S.D. 4.86) to 12.7 (4.76), P< 0.05], IL-6 by 91.4% [from
823.3 pg/ml (S.D. 31.67) to 71.0 (10.60), P< 0.05] and
TNF-a by 89.5% [from 876.0 pg/ml (S.D. 72.47) to 91.76
(33.08), P< 0.05] when compared with PBMCs with no
pretreatment (Fig. 1DF).
Some studies have demonstrated that S100A4 can ac-
tivate NF-kB and MAP kinases p38, JNK and ERK1/2 in
different cell types [8, 13]. Thus we were interested in
examining their signalling role in the S100A4-induced se-
cretion of TNF-a by PBMCs. TNF-a was significantly
reduced in PBMCs following treatment with an NF-kB in-
hibitor (n= 5) by 71.6% [from 763.5 pg/ml (S.D. 80.61) to
216.6 (83.53), P= 0.001], a p38 kinase inhibitor (n= 8) by
58.7% [from 825.6 pg/ml (S.D. 96.83) to 341.2 (65.90),
P< 0.05] and an ERK1/2 kinase inhibitor (n= 8) by
35.1% [from 825.6 pg/ml (S.D. 96.83) to 536.0 (74.46),
P< 0.05] (Fig. 2AC). Inhibition of JNK (n= 8) did not
alter the amount of TNF-a released by the S100A4-treated
PBMCs [from 825.6 pg/ml (S.D. 96.83) to 868.5 (160.5),
P= NS] (Fig. 2D). Moreover, treatment of PBMCs with
the S100A4 multimer induced phosphorylation of the
p38 and ERK1/2, but not JNK, in a time-dependent
manner, with significant increases observed at 15 and
30 min, respectively (Fig. 2E).
Discussion
In the present study we investigated the proinflammatory
role of S100A4. We demonstrated for the first time that
S100A4 protein induces the production of proinflamma-
tory cytokines such as TNF-a, IL-1b and IL-6 in mononu-
clear cells. S100A4 acted through TLR4 to activate
MyD88, the transcription factor NF-kB and the tyrosine
kinases ERK1/2 and p38. These results support the hy-
pothesis that S100A4 is involved in activation of the
immune response and inflammation in immune-mediated
diseases such as RA.
Although S100A4 has been primarily studied in cancers
[2], its potential roles in chronic inflammatory diseases
have recently been discovered [37]. It has been demon-
strated that several proinflammatory cytokines, in addition
to the chemokine CCL5 [regulated on activation, normal T
cell expressed and secreted (RANTES)], are responsible
for the induction of S100A4 release from different cell
types [17, 18]. Our previous studies have demonstrated
that S100A4 accumulates in the joints of patients with RA
and identified synovial fibroblasts and immune cells as
major sources of S100A4 [3, 4]. Furthermore, S100A4 ex-
pression was localized at sites of joint invasion. We have
also demonstrated that synovial fibroblasts are responsive
to the S100A4 multimer, which regulates apoptosis and
the production of matrix-degrading enzymes [3, 4]. In
agreement with our data, S100A4 has been shown to be
responsible for myeloid cell recruitment to sites of inflam-
mation in vivo [19] and thereby for the acceleration of in-
flammatory processes.
Here we demonstrate S100A4 as a mediator of innate
immune response and show a notable difference in the
proinflammatory effect within studied S100 proteins.
S100A4, S100A8 and S100A9 strongly up-regulated pro-
duction of proinflammatory cytokines in PBMCs, whereas
the proinflammatory effect of S100A12 on PBMCs was
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FIG. 1 PBMCs treated with S100A4 demonstrated significantly up-regulated production of TNF-a, IL-1b and IL-6 com-
pared with unstimulated cells (n= 8)
(AC) The production of these cytokines was markedly enhanced in response to S100A4 compared with S100A8 and
S100A12 but lower than S100A9. Blocking TLR4 (n= 5) or the MyD88 (n= 45) adaptor protein significantly down-
regulated the S100A4-induced secretion of (D) IL-1b, (E) IL-6 and (F) TNF-a in PBMCs. The protein levels in cell culture
supernatants were measured after 24 h. All results are expressed as the mean (S.E.M.). *P< 0.05, **P< 0.01,+P< 0.001.
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FIG. 2 S100A4 activates nuclear factor kB (NF-kB) and the kinases p38 and ERK1/2 in mononuclear cells from patients
with RA
(AC) Inhibition of NF-kB (n= 5), p38 and ERK1/2 kinases (n= 8) resulted in significant down-regulation of TNF-a pro-
duction, whereas (D) inhibition of the JNK MAP kinase (n= 8) did not alter the levels of TNF-a released by PBMCs treated
with S100A4. (E) The treatment of PBMCs with S100A4 multimer induced phosphorylation of p38 and ERK1/2, but not
JNK, with significant increases observed at 15 and 30 min, respectively. Protein levels in cell culture supernatants were
measured after 24 h. All results are expressed as the mean (S.E.M.). *P< 0.05, **P< 0.01.
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not clearly demonstrated. However, there are conflicting
reports of either elevated, reduced or unchanged produc-
tion of cytokines in different cell types treated by S100A12
[12, 14]. More importantly, we show that S100A8, and
particularly S100A4 and S100A9, share similar proinflam-
matory properties. It is well established that S100A9 is
commonly expressed as a heterodimer together with
S100A8, however, recent data have revealed that
S100A9 can also heterodimerise with S100A4 [15]. The
heterodimers as well as homodimers can interact with
the TLR4 or RAGE receptors [15]. According to Bjo¨rk
et al. [15], S100A4 homodimer interacts with the TLR4 at
a lower response level and with a slightly slower off-rate in
contrast to S100A9. We have demonstrated that the TLR4
receptor is engaged in the S100A4-mediated immune re-
sponse, however, the proinflammatory effect of S100A4 is
somewhat lower when compared with S100A9. In this
context we can speculate that this can be attributed to
the fact that S100A9 binds to TLR4 with a signal that is
higher than the response from S100A4. Our data on the
S100A4/TLR4 proinflammatory axis are in line with the
work of Vogl et al. [13], who showed that S100A8/9 up-
regulated TNF-a production in monocytes via TLR4.
Furthermore, we demonstrated that blocking S100A4
binding to RAGEs has no significant effect on inflamma-
tory cytokine production in PBMCs, as previously docu-
mented for some S100 proteins [8, 12]. Consistently
S100A12 was recently described as a TLR4 ligand that
induces monocyte activation, whereas the engagement
of RAGEs is not essential for S100A12-induced monocyte
activation [14].
In addition, we have demonstrated that the inhibition of
TLR4 signalling in S100A4-stimulated mononuclear cells
reduced the production of several cytokines by 2255%,
whereas inhibition of the adaptor protein MyD88
decreased cytokine production by 90%. Because signal-
ling through most TLR family members and the IL-1 re-
ceptor depends on the MyD88 signalling adaptor [20], it
can be hypothesized that some other receptors are
involved in S100A4-induced inflammation.
Furthermore, consistent with S100A8/9 [13], we demon-
strated that S100A4 induced TNF-a release from PBMCs
via activation of NF-kB and the MAP kinases ERK1/2 and
p38. This is in agreement with a previous study that
demonstrated phosphorylation of these MAP kinases
and downstream activation of NF-kB by S100A4 in chon-
drocytes [8]. Our findings suggest that extracellular
S100A4 binds to TLRs and activates MAP kinase signal-
ling pathways and the transcription factor NF-kB to stimu-
late the production of crucial proinflammatory cytokines in
mononuclear cells.
Conclusion
Taken together, our results suggest a possible mechan-
ism through which S100A4 mediates the innate immune
response. We demonstrated that mononuclear cells were
responsive to the extracellular S100A4 multimer. Our
results suggest that S100A4 is a novel TLR-4 ligand
that activates intracellular proinflammatory signalling
pathways. Therefore, targeting S100A4 may be a potential
therapy for immune-mediated diseases.
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Rheumatology key message
. In RA, S100A4 induces a proinflammatory pheno-
type of mononuclear cells via Toll-like receptor 4.
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